Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université de Sherbrooke

$17,500.00

Investigating the effects of hypertension and antihypertensive treatment on driving performance

EF 2014-15

Résumé
Background: The prevalence of hypertension is very high in North America. In fact, 33% of Americans and 20% of Canadians diagnosed. In these individuals, high blood pressure is often treated by pharmacological medication, which is susceptible to induce secondary effects, such as decrements in psychomotor function and perceptual skills. These skills are very relevant to vehicle driving, which is a daily task for most North Americans. In addition, hypertensive individuals have been found to be involved in more traffic collisions and more severe collisions compared to individuals with normal blood pressure. The mechanisms underlying these findings remain unclear. Objectives: The main objective of this study is to directly evaluate driving performance in hypertensive individuals. Findings may help in understanding the increased risk faced by hypertensive individuals at the wheel. Secondary objectives include the development of research methodologies in this population. By doing so, we believe to be the first group to measure driving performances of hypertensive individuals. Protocol: Hypertensive individuals are often medicated, we will therefore observe participants before beginning treatment and every month following for a total duration of three months on a driving simulator. Driving simulators provide a safe, cost-effective and validated tool in driving research. Eligible participants must be diagnosed with hypertension and beginning pharmacological treatment (i.e. angiotensin-converting enzyme inhibitors; often, the first type of medication prescribed)) with a valid driving permit. An age-matched un-medicated control group will also be followed to control for potential confounding driving simulator adaptations.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
331504
Name
Gallant François
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the effects of hypertension and antihypertensive treatment on driving performance
Programtype2
Studentship Programs
Orgnameinp2
Université de Sherbrooke
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antihypertensive Treatment; Autonomic Nervous System; Driving; Driving Simulator; Hypertension; Psychophysiology; Stress
Abstract
Background: The prevalence of hypertension is very high in North America. In fact, 33% of Americans and 20% of Canadians diagnosed. In these individuals, high blood pressure is often treated by pharmacological medication, which is susceptible to induce secondary effects, such as decrements in psychomotor function and perceptual skills. These skills are very relevant to vehicle driving, which is a daily task for most North Americans. In addition, hypertensive individuals have been found to be involved in more traffic collisions and more severe collisions compared to individuals with normal blood pressure. The mechanisms underlying these findings remain unclear. Objectives: The main objective of this study is to directly evaluate driving performance in hypertensive individuals. Findings may help in understanding the increased risk faced by hypertensive individuals at the wheel. Secondary objectives include the development of research methodologies in this population. By doing so, we believe to be the first group to measure driving performances of hypertensive individuals. Protocol: Hypertensive individuals are often medicated, we will therefore observe participants before beginning treatment and every month following for a total duration of three months on a driving simulator. Driving simulators provide a safe, cost-effective and validated tool in driving research. Eligible participants must be diagnosed with hypertension and beginning pharmacological treatment (i.e. angiotensin-converting enzyme inhibitors; often, the first type of medication prescribed)) with a valid driving permit. An age-matched un-medicated control group will also be followed to control for potential confounding driving simulator adaptations.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gallant, François
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~